^
Association details:
| Biomarker: | GNAQ mutation |
|---|---|
| Cancer: | Uveal Melanoma |
| Drug: | Mektovi (binimetinib) (MEK inhibitor) + sotrastaurin (AEB071) (PKC inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma
Excerpt:
When combined with AEB071, the two agents CGM097 (p53-MDM2 inhibitor) and RAD001 (mTORC1 inhibitor) demonstrated greater activity than single agents, with tumor regression observed in several UM PDXs...we have discovered using our unique panel of preclinical models that combinations between PKC/mTOR inhibitors and PKC/p53-MDM2 inhibitors are two novel and very effective therapeutic approaches for this disease....In conclusion, our in vitro findings show that co-inhibition of PKC and mTORC1 or PKC and p53-MDM2 are effective combination strategies for GNAQ/11 mutated UM models.
DOI:
10.18632/oncotarget.9552
